Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors
August 25 2021 - 4:00PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, announced today
that it has appointed Nancy Whiting, Pharm.D., to its board of
directors. Dr. Whiting brings over 17 years of biotechnology
industry expertise in drug and portfolio development, as well as
significant strategic leadership experience.
“I am delighted to welcome Nancy to our board of directors,”
said Rachel Haurwitz, Ph.D., Caribou’s president and chief
executive officer. “She has significant experience in all phases of
drug development and commercialization with particular expertise in
oncology, which is highly relevant to Caribou as we advance our
pipeline of chRDNA-edited allogeneic cell therapies for the
potential treatment of a variety of hematologic malignancies and
solid tumors.”
“I am excited by the prospects of Caribou’s differentiated
genome-editing technology and its initial applications in
off-the-shelf cell therapies that have the potential to broaden
treatment options for cancer patients,” said Dr. Whiting. “I look
forward to working with the Caribou team and other members of its
board of directors to help build and grow the company as it
develops its product candidates and brings these therapies to
patients as expeditiously as possible.”
Dr. Whiting most recently served as executive vice president,
Corporate Strategy, Alliances and Communication for Seagen Inc.
(formerly Seattle Genetics). She held roles of increasing
responsibility at the company in early- and late-stage clinical
development and medical affairs, which included leading the
development of all of Seagen’s late-stage assets, namely ADCETRIS,
PADCEV, TUKYSA, tisotumab vedotin, and ladiratizumab vedotin. Prior
to her tenure in the biopharmaceutical industry, she had a career
in clinical pharmacy serving as a clinical oncology pharmacist at
Seattle Cancer Care Alliance, and previously as the staff
pharmacist for the Bone Marrow Transplant and Acute Leukemia
department at Vancouver Hospital. She received a Pharm.D. degree
from the University of Washington and a B.S. in Pharmacy from the
University of British Columbia, Vancouver.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Type II CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems
occasionally edit unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
chRDNAs (pronounced “chardonnays”), RNA-DNA hybrid guides that
direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of the chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou is a
clinical-stage CRISPR genome-editing biopharmaceutical company
dedicated to transforming the lives of patients with devastating
diseases by applying the company’s proprietary chRDNA technology
toward the development of next-generation, genome-edited cell
therapies. The company is developing a pipeline of genome-edited,
off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of
both hematologic malignancies and solid tumors against cell surface
targets for which autologous CAR-T cell therapeutics have
previously demonstrated clinical proof of concept, as well as
additional emerging targets.
Forward-Looking Statements This press release
contains forward-looking statements, within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, without limitation, statements
related to Caribou’s pipeline of cell therapies, potential
treatments, and expectations regarding its business. Management
believes that these forward-looking statements are reasonable as
and when made. However, such forward-looking statements are
subject to risks and uncertainties, and actual results may differ
materially from any future results expressed or implied by the
forward-looking statements. Risks and uncertainties include without
limitation the risks inherent in drug development such as those
associated with the initiation, cost, timing, progress and results
of current and future research and development programs,
preclinical and clinical trials, as well as other risk factors
described from time to time in Caribou’s filings with the
Securities and Exchange Commission, including its final prospectus
filed on July 23, 2021. In light of the significant uncertainties
in these forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. Except
as required by law, Caribou undertakes no obligation to update
publicly any forward-looking statements for any reason.
For more information about Caribou, visit www.cariboubio.com and
follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are registered
trademarks of Caribou Biosciences, Inc.
Caribou Biosciences, Inc. Media
Contact: |
Caribou Biosciences, Inc. Investor
Relations Contact: |
Greg Kelley |
Elizabeth Wolffe, Ph.D., and
Sylvia Wheeler |
Ogilvy |
Wheelhouse LSA |
gregory.kelley@ogilvy.com |
lwolffe@wheelhouselsa.com |
617-461-4023 |
swheeler@wheelhouselsa.com |
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024